<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1008">
  <stage>Registered</stage>
  <submitdate>6/12/2005</submitdate>
  <approvaldate>6/12/2005</approvaldate>
  <nctid>NCT00263042</nctid>
  <trial_identification>
    <studytitle>Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes</studytitle>
    <scientifictitle>Randomized, Multinational, Multicenter, Double-blind, Placebo-controlled, Two-arm Parallel Group Trial of Rimonabant 20 mg OD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients With Clustering Risk Factors</scientifictitle>
    <utrn />
    <trialacronym>CRESCENDO</trialacronym>
    <secondaryid>2005-002942-20</secondaryid>
    <secondaryid>EFC5826</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cardiovascular Disease</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Rimonabant
Treatment: drugs - Placebo (for Rimonabant)

Experimental: Rimonabant - Rimonabant 20 mg once daily

Placebo Comparator: Placebo - Placebo (for Rimonabant) once daily.


Treatment: drugs: Rimonabant
Tablet, oral administration

Treatment: drugs: Placebo (for Rimonabant)
Tablet, oral administration

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>First occurrence of any of myocardial infarction, stroke or cardiovascular (CV) death</outcome>
      <timepoint>From randomization up to common study end date (33-50 months)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>First occurrence of any of myocardial infarction, stroke, CV death, and CV hospitalization</outcome>
      <timepoint>From randomization up to common study end date (33-50 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All-cause mortality</outcome>
      <timepoint>From randomization up to common study end date (33-50 months)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Waist circumference &gt;102 cm (40 inches) males, &gt;88 cm (35 inches) females, with one
        coronary heart disease (CHD) equivalent or two major risk factors for cardiovascular
        disease.

          -  CHD equivalents:

               -  Recent (within 3 years)documented heart attack

               -  Documented symptomatic coronary artery disease

               -  Recent (within 3 years) ischemic cerebrovascular episode (stroke or TIA)

               -  Documented symptomatic peripheral arterial disease

          -  Major risk factors:

               -  Documented type 2 diabetes mellitus

               -  Metabolic syndrome (NCEP criteria)

               -  Asymptomatic cerebrovascular, renal, or peripheral arterial disease, or past
                  abdominal aortic aneurysm repair

               -  Elevated high-sensitivity C-reactive protein

               -  Age &gt; or = 65 years for males, age &gt; or = 70 years for females</inclusivecriteria>
    <inclusiveminage>55</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Obesity of known endocrine origin

          -  Pregnant or breastfeeding women

          -  Very low calorie diet or weight loss surgery within past 6 months

          -  Presence of any severe medical or psychological condition that, in the opinion of the
             investigator, would compromise the patient's safe participation, including
             uncontrolled serious psychiatric illness

          -  Likely cardiovascular intervention within next 1 month

          -  Allergy to rimonabant or excipients, or prior participation in a rimonabant trial

          -  Receipt of investigational product within past 30 days</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>18695</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>sanofi-aventis Australia &amp; New Zealand administrative office - Macquarie Park</hospital>
    <postcode> - Macquarie Park</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Diegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago de Chile</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Shanga√Ø</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Santafe de Bogota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Horsholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsinki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong-Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Mumbai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Natanya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuala Lumpur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Gouda</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Lysaker</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Peru</country>
      <state>Lima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Makati City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Porto Salvo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucuresti</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Midrand</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Bromma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Geneva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Tunisia</country>
      <state>Megrine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Guildford</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sanofi</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective is to show whether rimonabant reduces the risk of a heart attack (MI),
      stroke, or death from an MI or stroke in patients with abdominal obesity with other
      cardiovascular (CV) risk factors.

      The secondary objective is to show whether rimonabant reduces the risk of MI, stroke, CV
      death, or CV hospitalization in these patients.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00263042</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Eric Topol, MD</name>
      <address>Scripps Clinic</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>